For instance, among the top actively rewired cell surface marker genes, CD7 has already been utilised as a target in chimeric antigen receptor T‐cell (CAR‐T) therapy for refractory/relapsed T‐ALL, and CXCR4 monoclonal antibodies were also used in a clinical trial for refractory/relapsed T‐ALL [38, 39, 40]. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.